Investigating the long-term effects of antiviral therapy on hearing and development in children with congenital CMV.
Longitudinal CMV
This study is looking at kids who were treated with a medicine called valganciclovir for congenital cytomegalovirus (CMV) disease when they were babies, to see if the good effects on their hearing and development last as they grow into their teenage years.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10915385 on NIH RePORTER |
What this research studies
This research focuses on children who were treated with valganciclovir for symptomatic congenital cytomegalovirus (CMV) disease during infancy. It aims to determine if the positive effects of this treatment on hearing and developmental outcomes, observed up to age two, continue into adolescence. The study will involve returning participants from a previous trial to assess their hearing, development, and potential long-term side effects of the antiviral therapy. This approach will help understand the durability of treatment benefits and any associated risks as these children grow older.
Who could benefit from this research
Good fit: Ideal candidates for this research are adolescents who were treated for symptomatic congenital CMV disease during infancy and are now approaching their 12th birthday.
Not a fit: Patients who were not diagnosed with congenital CMV disease or did not receive antiviral treatment during infancy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide valuable insights into the long-term effectiveness and safety of antiviral therapy for children with congenital CMV, potentially improving treatment protocols.
How similar studies have performed: Previous studies have shown positive outcomes from antiviral treatment in infants with congenital CMV, but this research aims to explore the long-term effects, making it a novel inquiry.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Kimberlin, David W — University of Alabama at Birmingham
- Study coordinator: Kimberlin, David W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.